Salud financiera de hoja de balance de Oxford BioDynamics

Salud financiera controles de criterios 6/6

Oxford BioDynamics tiene un patrimonio de los accionistas total de £6.1M y una deuda total de £0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son £16.1M y £10.1M respectivamente.

Información clave

Ratio deuda-patrimonio

UK£0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	UK£5.25m
Patrimonio	UK£6.06m
Total pasivo	UK£10.07m
Activos totales	UK£16.13m

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Jan 18

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oct 08

Recent updates

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Jan 18

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oct 08

Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?

Sep 21

Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans

May 24

We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate

Dec 07

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (£7.2M) de OBD superan a sus pasivos a corto plazo (£4.0M).

Pasivo a largo plazo: Los activos a corto plazo de OBD (£7.2M) superan a sus pasivos a largo plazo (£6.1M).

Historial y análisis de deuda-patrimonio

Nivel de deuda: OBD está libre de deudas.

Reducción de la deuda: OBD no ha tenido ninguna deuda en los últimos 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: OBD tiene suficiente cash runway para 7 meses según el flujo de caja libre último declarado, pero desde entonces ha obtenido capital adicional.

Pronóstico de cash runway: Se prevé que OBD disponga de suficiente cash runway para 5 meses según las estimaciones de flujo de caja libre, aunque ha obtenido desde entonces capital adicional.

Salud financiera de hoja de balance de Oxford BioDynamics

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?

Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans

We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate

Recent updates

OBD Develops Multi-Cancer Diagnostic Test for Dogs

Oxford BioDynamics Plc to Report First Half, 2024 Results on Jun 18, 2024

Oxford BioDynamics Plc Opens Clinical Testing Facility in the UK to Perform EpiSwitch Prostate Screening (PSE) Blood Test

Oxford BioDynamics Plc has filed a Follow-on Equity Offering in the amount of £9 million.

Oxford BioDynamics Plc, Annual General Meeting, Mar 27, 2024

Here's Why We're Watching Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Full year 2023 earnings released: UK£0.073 loss per share (vs UK£0.067 loss in FY 2022)

Oxford BioDynamics Plc to Report Fiscal Year 2023 Results on Jan 17, 2024

New minor risk - Financial data availability

Non-Executive Director recently sold UK£298k worth of stock

Non-Executive Director recently sold UK£52k worth of stock

Oxford BioDynamics Plc Launches 94% Accurate PSE Test in US and UK

New major risk - Shareholder dilution

First half 2023 earnings released: UK£0.032 loss per share (vs UK£0.031 loss in 1H 2022)

Oxford BioDynamics Plc to Report First Half, 2023 Results on May 30, 2023

Oxford BioDynamics Plc Announces Prostate Screening EpiSwitch® Blood Test Significantly Enhances Overall Detection Accuracy for At Risk Men

Non-Executive Director recently bought UK£51k worth of stock

Full year 2022 earnings released: UK£0.067 loss per share (vs UK£0.072 loss in FY 2021)

Oxford BioDynamics Plc, Annual General Meeting, Mar 30, 2023

Oxford BioDynamics Plc Announces Initial Assessment of EpiSwitch Assay in Amyotrophic Lateral Sclerosis Trial

Less than half of directors are independent

Oxford BioDynamics Plc, Annual General Meeting, Oct 27, 2022

Here's Why We're A Bit Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Situation

Oxford BioDynamics plc Announces US Reimbursement Code for CiRT Now Available

First half 2022 earnings released

Oxford Biodynamics plc Checkpoint Inhibitor Response Test (Episwitch® Cirt) Now Available in the UK

Oxford BioDynamics Plc to Report First Half, 2022 Results on Jun 28, 2022

Oxford BioDynamics Plc Presents Additional Data at ASCO 2022

Less than half of directors are independent

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Announces Successful Clinical Validation and US Launch of its Checkpoint Inhibitor Response Test

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Oxford BioDynamics Plc Provides Update on EpiSwitch CST and CiRT tests

Is Oxford BioDynamics (LON:OBD) In A Good Position To Invest In Growth?

First half 2021 earnings released: UK£0.033 loss per share (vs UK£0.022 loss in 1H 2020)

Oxford BioDynamics (LON:OBD) Is In A Good Position To Deliver On Growth Plans

Oxford BioDynamics Plc Publishes Results of Biomarker Discovery Program Being Used for Development of Its EpiSwitch Covid-19 Severity Test

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Full year 2020 earnings released: UK£0.047 loss per share (vs UK£0.03 loss in FY 2019)

Oxford BioDynamics Plc, Annual General Meeting, Mar 24, 2021

Oxford BioDynamics Plc to Report Fiscal Year 2020 Results on Jan 28, 2021

Oxford BioDynamics Plc Announces Retirement of Christian Hoyer Millar from Board of Directors

Oxford BioDynamics Plc to Expand Strategic Focus Beyond Biomarker Discovery to Development and Commercialization of Laboratory Tests

We're Not Very Worried About Oxford BioDynamics' (LON:OBD) Cash Burn Rate

New 90-day low: UK£0.70

Oxford BioDynamics Announces Strategic Partnership with Boca Biolistics in Order to Advance Episwitch™ Disease Severity Program for COVID-19

New 90-day high: UK£1.05

New 90-day high - UK£0.92

New 90-day high - UK£0.91

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera